Adding pembrolizumab to radiotherapy and surgery can improve disease-free survival in patients with certain types of sarcoma.

Investigators from the University of Turin have developed and characterized a new murine immunocompetent model of Usp18-knockout leiomyosarcoma (LMS). LMS is a rare malignant soft tissue cancer with ...

A new study has shown that adding a drug called pembrolizumab to standard treatments can improve survival for people with certain sarcomas.